Tag: results

Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board

GLYFADA, Greece, June 11, 2025 (GLOBE NEWSWIRE) -- Globus Maritime Limited ("Globus," the “Company”, (“we,” or “our”), (NASDAQ: GLBS), a dry bulk shipping company, announced today that it will release financial results for the three‐month period ended March 31, 2025, after the market closes in New York on Monday, June 16, 2025.

MIAMI BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the closing of its previously announced underwritten public offering of 3,160,000 shares of common stock. In addition, the underwriter has exercised in full its option to purchase an additional 474,000 shares of common stock. The proceeds from the offering, after estimated expenses, are estimated to be approximately $13.8 million.

DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce a change to its regular dividend payment frequency from quarterly to monthly beginning in July 2025.

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- June 11, 2025 - Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, inclusive (the “Class Period”).

WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the license and supply agreement between them. The latter could result in the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and a reduction in the transfer price for Biofrontera Inc.’s licensed products sold in the US.